eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity


Autoria(s): NAGASSAKI, S.; HERCULANO, R. D.; GRAEFF, C. F. O.; TANUS-SANTOS, J. E.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2009

Resumo

Statins have pleiotropic effects, including endothelial nitric oxide synthase (eNOS) upregulation and increased nitric oxide formation, which can be modulated by a genetic polymorphism in the promoter region of the eNOS gene (T-786C). Here, we report our investigation of whether this polymorphism modulates the effects of atorvastatin on the fluidity of erythrocyte membranes. We genotyped 200 healthy subjects (males, 18-60 years of age) and then randomly selected 15 of these with the TT genotype and 15 with the CC genotype to receive placebo or atorvastatin (10 mg/day oral administration) for 14 days. Cell membrane fluidity was evaluated by electron paramagnetic resonance (EPR) and spin-labeling method. The EPR spectra were registered on a VARIAN-E4 spectrometer. Thiobarbituric acid-reactive species (TBA-RS) and plasma membrane cholesterol were determined in the erythrocytes. Atorvastatin reduced membrane fluidity in CC subjects (P < 0.05) but not in those with the TT genotype (P > 0.05). While no significant differences were found in plasma membrane cholesterol concentrations, higher TBA-RS concentrations were found in the CC subjects than in the TT subjects (P < 0.05). These findings suggest that a short treatment with atorvastatin is disadvantageous to subjects with the CC genotype for the T-786C polymorphism compared to those with TT genotype, at least in terms of the hemorheological properties of erythrocytes.

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq-Brazil)

Identificador

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, v.65, n.4, p.385-392, 2009

0031-6970

http://producao.usp.br/handle/BDPI/30190

10.1007/s00228-008-0602-7

http://dx.doi.org/10.1007/s00228-008-0602-7

Idioma(s)

eng

Publicador

SPRINGER

Relação

European Journal of Clinical Pharmacology

Direitos

restrictedAccess

Copyright SPRINGER

Palavras-Chave #Endothelial nitric oxide synthase #EPR #Genotypes #Nitric oxide #Polymorphisms #Statins #NITRIC-OXIDE SYNTHASE #COA REDUCTASE INHIBITORS #RED-BLOOD-CELLS #SODIUM-LITHIUM COUNTERTRANSPORT #TYPE-2 HYPERCHOLESTEROLEMIA #FAMILIAL HYPERCHOLESTEROLEMIA #ESSENTIAL-HYPERTENSION #STATINS #PLASMA #LIPIDS #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion